Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM for Mild/Moderate COPD
NCT01486186Phase 2Unknown
- Sponsor
- Henan University of Chinese Medicine
- Start
- Dec 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Baofeikang, bufei fang and bufei yishen granule in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Henan University of Chinese Medicine. Primary endpoints: Frequency of Exacerbations at 104 weeks and Forced Expiratory Volume in 1 Second at 104 weeks. Status: unknown.
02
Drugs
Baofeikangbufei fangbufei yishen granule
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01486186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486186.